Amylyx has presented new exploratory analyses from the Phase II PREVENT and Phase IIb trials of avexitide for PBH treatment.

Crinetics Pharmaceuticals has revealed new data from its clinical development programme for Palsonify, an oral treatment for acromegaly.

Takeda’s oral narcolepsy drug, oveporexton, has met the primary and secondary endpoints in two Phase III trials. The FirstLight (NCT06470828) and RadiantLight (NCT06505031) trials both met all their ...

LEO Pharma has reported outcomes from the 16-week interim analysis of the Phase IIIb ADHAND trial of tralokinumab for hand atopic dermatitis (AD).

UK & Ireland, experts provided insights on market trends within the clinical trial industry and advice on engagement strategies.

UroGen Pharma has completed the enrolment of subjects in its Phase III UTOPIA trial, which is evaluating UGN-103 for intravesical solution.

XyloCor has dosed the first subject in the multi-centre, randomised Phase IIb EXACT-2 trial to assess the gene therapy candidate, XC001.

Findings from a Phase I trial initiated by Dana-Farber Cancer Institute have showed NeoVaxMI's improved immune response in melanoma patients.

Arrowhead has dosed the first participant in the Phase III YOSEMITE trial of zodasiran, under development for treating HoFH.

A panel at CTO East Coast discussed the regulatory changes impacting oncology trials and how these can be managed.

Pfizer and Astellas’ Xtandi (enzalutamide) has improved overall survival (OS) in patients with nmHSPC, but only as a combination therapy.

Rhythm Pharmaceuticals is advancing its oral obesity drug bivamelagon to Phase III studies after it significantly reduced body mass index (BMI) in all three doses.